Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 26
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Zhang, Hui Liu, Tao Zhang, Zhen Payne, Samuel H. Zhang, Bai McDermott, Jason E. Zhou, Jian-Ying Petyuk, Vladislav A. Chen, Li Ray, Debjit Sun, Shisheng Yang, Feng Chen, Lijun Wang, Jing Shah, Punit Cha, Seong Won Aiyetan, Paul Woo, Sunghee Tian, Yuan Gritsenko, Marina A. Clauss, Therese R. Choi, Caitlin Monroe, Matthew E. Thomas, Stefani Nie, Song Wu, Chaochao Moore, Ronald J. Yu, Kun-Hsing Tabb, David L. Fenyö, David Bafna, Vineet Wang, Yue Rodriguez, Henry Boja, Emily S. Hiltke, Tara Rivers, Robert C. Sokoll, Lori Zhu, Heng Shih, Ie-Ming Cope, Leslie Pandey, Akhilesh Zhang, Bing Snyder, Michael P. Levine, Douglas A. Smith, Richard D. Chan, Daniel W. and Rodland, Karin D. 2016. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell, Vol. 166, Issue. 3, p. 755.

    Kan, Casina W. S. Howell, Viive M. Hahn, Michael A. and Marsh, Deborah J. 2015. Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes, Chromosomes and Cancer, Vol. 54, Issue. 1, p. 1.

    Howell, Viive M. 2014. Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?. Seminars in Cell & Developmental Biology, Vol. 27, p. 106.

    Altman, Alon D Nelson, Gregg S Ghatage, Prafull McIntyre, John B Capper, David Chu, Pamela Nation, Jill G Karnezis, Anthony N Han, Guangming Kalloger, Steve E and Köbel, Martin 2013. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, Vol. 26, Issue. 9, p. 1255.

    Conklin, Chris MJ and Gilks, C Blake 2013. Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. Expert Review of Obstetrics & Gynecology, Vol. 8, Issue. 1, p. 67.

    Gurung, Ananta Hung, Tawny Morin, Jason and Gilks, C Blake 2013. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology, Vol. 62, Issue. 1, p. 59.

    Bromley, Amy B. Altman, Alon D. Chu, Pamela Nation, Jill G. Nelson, Gregg S. Ghatage, Praful Kalloger, Steve E. Han, Guangming and Köbel, Martin 2012. Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, Vol. 31, Issue. 5, p. 397.

    Malisic, Emina Jankovic, Radmila and Jakovljevic, Ksenija 2012. Detection and genotyping of human papillomaviruses and their role in the development of ovarian carcinomas. Archives of Gynecology and Obstetrics, Vol. 286, Issue. 3, p. 723.

    Smith, Cassandra L. Oh, Herin and Stamenović, Dimitrije 2012. Encyclopedia of Analytical Chemistry.

    Dobrzycka, B. Terlikowski, S. J. Kinalski, M. Kowalczuk, O. Niklinska, W. and Chyczewski, L. 2011. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Annals of Oncology, Vol. 22, Issue. 5, p. 1133.

    Jazaeri, Amir A. Bryant, Jennifer L. Park, Hong Li, Hui Dahiya, Neetu Stoler, Mark H. Ferriss, James Stuart and Dutta, Anindya 2011. Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma. Neoplasia, Vol. 13, Issue. 10, p. 899.

    Köbel, Martin and Huntsman, David 2011. Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, Vol. 4, Issue. 1, p. 275.

    Köbel, Martin Turbin, Dmitry Kalloger, Steve E. Gao, Dongxia Huntsman, David G. and Gilks, C. Blake 2011. Biomarker Expression in Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, Vol. 30, Issue. 4, p. 366.

    Lee, Peng Jain, Shilpa Pincus, Matthew R. and Xu, Ruliang 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods.

    McAlpine, J.N. El Hallani, S. Lam, S.F. Kalloger, S.E. Luk, M. Huntsman, D.G. MacAulay, C. Gilks, C.B. Miller, D.M. and Lane, P.M. 2011. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. Gynecologic Oncology, Vol. 120, Issue. 3, p. 385.

    Schlosshauer, Peter W. Deligdisch, Liane Penault-Llorca, Frédérique Fatemi, Delaram Qiao, Rui Yao, Shen Pearl, Meghan Yang, Zhen Sheng, Tao and Dong, Jianli 2011. Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas. International Journal of Gynecological Pathology, Vol. 30, Issue. 1, p. 22.

    Vereczkey, Ildikó Serester, Orsolya Dobos, Judit Gallai, Mónika Szakács, Orsolya Szentirmay, Zoltán and Tóth, Erika 2011. Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors. Pathology & Oncology Research, Vol. 17, Issue. 3, p. 551.

    Cooke, S L Ng, C K Y Melnyk, N Garcia, M J Hardcastle, T Temple, J Langdon, S Huntsman, D and Brenton, J D 2010. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene, Vol. 29, Issue. 35, p. 4905.

    Crum, Christopher P. and Xian, Wa 2010. Bringing the p53 signature into focus. Cancer, Vol. 116, Issue. 22, p. 5119.

    Gilks, C. Blake 2010. Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma. Journal of Oncology, Vol. 2010, p. 1.

  • Expert Reviews in Molecular Medicine, Volume 10
  • 2008, e22

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

  • Martin Köbel (a1) (a2), David Huntsman (a1) and C. Blake Gilks (a1)
  • DOI:
  • Published online: 01 August 2008

Ovarian carcinomas show more morphological heterogeneity than adenocarcinomas of any other body site. It has recently become clear that the morphologically defined subtypes of ovarian carcinoma are distinct diseases, with different risk factors, molecular events during oncogenesis, likelihood of spread, responses to chemotherapy, and outcomes. This review focuses on molecular abnormalities (in genes expressing BRCA1/2, TP53 and RB1/CCND1/CDKN2A/E2F) found in high-grade serous carcinomas of the ovary, which account for most ovarian cancer deaths. These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice.

Corresponding author
*Corresponding author: C. Blake Gilks, Department of Pathology, Room 1207 1st floor JPPN, Vancouver General Hospital, 855 West 12th Ave, Vancouver, BC, Canada, V5Z 1M9. Tel.: +1 (604) 875 4901; Fax: +1 (604) 875 4797; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2N. Auersperg (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255-288

3C.P. Crum (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5, 35-44

5J.D. Seidman (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23, 41-44

7M. Takano (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94, 1369-1374

8A. duBois (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95, 1320-1329

10I. Shih and R.J. Kurman (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164, 1511-1518

14M. Al Hussaini (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44, 109-115

15A. Malpica (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28, 496-504

16A. Malpica (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31, 1168-1174

17G. Singer (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484-486

18G. Singer (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29, 218-224

19M.A. Crispens (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99, 3-10

20D.M. Gershenson (2006) Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108, 361-368

22C.B. Gilks (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23, 200-205

23F. Medeiros (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30, 230-236

24D.W. Kindelberger (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31, 161-169

27A.N. Tutt (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70, 139-148

28A. Tutt (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20, 4704-4716

29B. Modan (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345, 235-240

30R. Moslehi (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66, 1259-1272

31H.A. Risch (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68, 700-710

32J.L. Hilton (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94, 1396-1406

33J.Z. Press (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17

34P.A. Shaw (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21, 407-411

36N. Collins (1997) Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 76, 1150-1156

37L.A. Brown (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100, 264-270

38A. Raouf (2005) Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97, 1302-1306

39J. Boyd (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283, 2260-2265

40Y. Ben David (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20, 463-466

41J.E. Quinn (2007) BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 13, 7413-7420

42A. Bhattacharyya (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275, 23899-23903

43S.A. Narod and J. Boyd (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14, 19-26

44H. Farmer (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921

45W. Sakai (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120

46S.L. Edwards (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115

47E.M. Swisher (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68, 2581-2586

48B. Vogelstein and K.W. Kinzler (2004) Cancer genes and the pathways they control. Nat Med 10, 789-799

49D. Xing and S. Orsulic (2006) A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 66, 8949-8953

51R. Wu (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11, 321-333

52A. Garcia (2000) Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. Int J Gynecol Pathol 19, 152-157

53R. Salani (2008) Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 18, 487-491

54L. Havrilesky (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21, 3814-3825

55C.S. Moreno (2007) Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas. PLoS ONE 2, e441

59H. Lassus (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91, 504-512

62T. Bonome (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65, 10602-10612

63C.B. Gilks (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96, 684-694

64I. Meinhold-Heerlein (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24, 1053-1065

65S. Kommoss (2007) Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Br J Cancer 96, 306-313

67D. Katsaros (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94, 685-692

68J.E. Armes (2005) Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24, 363-368

69A. Bali (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10, 5168-5177

71K.L. Gorringe (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13, 4731-4739

72S.L. Harris and A.J. Levine (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908

73K. Nakayama (2007) Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120, 2613-2617

74A. Staebler (2006) Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45, 905-917

75S. Pelengaris (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2, 764-776

78M.A. Bookman (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21, 283-290

79E.K. Riener (2004) The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 95, 89-94

80M. Tuefferd (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2, e1138

81D. Mayr (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48, 149-156

82C.H. Lee (2005) Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24, 147-152

83J.S. Berek (2003) Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21, 168s-174s

84L. Calzone (2008) A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4, 173

85H.K. Dressman (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25, 517-525

86R. Agarwal and S.B. Kaye (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516

87C.M. Perou (2000) Molecular portraits of human breast tumours. Nature 406, 747-752

88A.A. Alizadeh (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511

91D.A. Bell (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl. 2), S19-S32

92C.P. Crum (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19, 3-9

H. Naora (2007) The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 9, 1-12

C.A. Barton (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109, 129-139

D.S. Tan (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7, 925-934

Y.L. Hu (2003) Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 95, 733-740

C.A. Sherman-Baust (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377-386

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *